Effects of intranasal 17β-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial

  title={Effects of intranasal 17$\beta$-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial},
  author={Y. Engin-{\"U}st{\"u}n and Y. {\"U}st{\"u}n and M. M. Meydanlı and A. Kafkaslı},
  journal={Gynecological Endocrinology},
  pages={676 - 679}
Aim. To compare the effects of 17β-estradiol given intranasally (intranasal E2) and raloxifene on serum lipid profile and fibrinogen in hypercholesterolemic postmenopausal women. Methods. The study population consisted of 46 women after menopause. The placebo group (n = 11) was given calcium, while the intervention groups were given intranasal E2 (Aerodiol®; Servier, Chambray-les-Tours, France) (n = 16) or raloxifene (Evista®; Lilly SA, Madrid, Spain) (n = 19). Blood lipids and fibrinogen were… Expand
3 Citations
Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials.
There is robust evidence that the appropriate treatment of dyslipidaemia substantially reduces cardiovascular disease-related morbidity and mortality. Raloxifene is a selective oestrogen receptorExpand
It was shown that ralofen had no significant effects on serum lipids levels and triglyceride and cholesterol increased were in normal and borderline limits that don't have clinical importance. Expand
Raloxifene and lipid profiles in Postmenopausal Women: A Systematic Review
The consistent results on reduction of LDL cholesterol and total cholesterol in raloxifene using postmenopausal women were confirmed, however, the effect of ral oxifene on other components of lipid profile and endothelial function were still remaining controversial. Expand


Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women
Both CEE and raloxifene exert significant effects on the lipid and coagulation profile and CEE had a more significant effect on fibrinolysis than ral oxifene. Expand
A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Findings support the position of the National Cholesterol Education Program that estrogen replacement, with a progestin where indicated, should be given consideration as a therapeutic option for the management of hypercholesterolemia in postmenopausal women. Expand
Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
Data on safety and lipid-lowering effects are needed before raloxifene and statin coadministration may be considered as therapeutic interventions for treating postmenopausal women to achieve National Cholesterol Education Program-Adult Treatment Panel III treatment guidelines. Expand
Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women.
In postmenopausal women with hypercholesterolemia, therapy with estrogen plus progestin has beneficial effects on lipoprotein levels, and Hormone therapy may be an effective alternative to treatment with simvastatin, especially in women with normal triglyceride levels. Expand
The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.
HRT and raloxifene lower serum homocysteine levels to a comparable extent in postmenopausal women, and the relationship between elevated C-reactive protein levels with HRT and cardiovascular disease events requires further study. Expand
Effect of Pulsed Estrogen Therapy on Hemostatic Markers in Comparison with Oral Estrogen Regimen in Postmenopausal Women
Nasal 17β-estradiol had no effect on the coagulation markers, except a moderate increment in PAI-1, and oral estrogens elicited a decrement in both VIIa-rTF and PAi-1; however, those changes did not surpass normal limits. Expand
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease. Expand
Selective estrogen-receptor modulators.
  • F. Cosman
  • Medicine
  • Clinics in geriatric medicine
  • 2003
In postmenopausal women, consideration should be given to the addition of an agent that is shown to have efficacy against fractures (such as bisphosphonates), even while these women are on tamoxifen; however, the effect on fracture risk is unclear. Expand
Effects of oestrogen receptor‐active compounds on lipid metabolism
The purpose of this article is to discuss the mechanism of action of Tamoxifen, Raloxifene and Tibolone and their effects on lipid metabolism. Expand
Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.
Of 11 atherothrombotic biomarkers assessed at baseline, the total cholesterol–HDL-C ratio and CRP were the strongest independent predictors of development of peripheral arterial disease. Expand